
Vigil Neuroscience (VIGL) Stock Forecast & Price Target
Vigil Neuroscience (VIGL) Analyst Ratings
Bulls say
Vigil Neuroscience Inc is positioned favorably in the biotechnology sector due to its commitment to developing disease-modifying therapeutics targeting neurodegenerative diseases, with VG-3927 demonstrating a promising safety profile and once-daily dosing potential. Biomarker data from the IGNITE study indicates a significant dose-dependent reduction in the TREM2 levels in cerebrospinal fluid, suggesting robust target engagement and supporting the efficacy of iluzanebart in slowing disease progression. Furthermore, the comprehensive approach involving blood/CSF biomarkers and imaging outcomes enhances Vigil's prospects for compelling regulatory filings, reinforcing a positive outlook on its stock performance.
Bears say
Vigil Neuroscience has experienced significant downward pressure on its stock, with shares declining by 26% following the ALEC TREM2 data readout. The company reported a substantial net loss of $23.8 million, translating to a GAAP EPS of $(0.57), which fell short of analyst expectations. Furthermore, the increase in the valuation discount rate to 35% has led to a revised stock target of $13, significantly lower than previous estimates, indicating a challenging financial outlook for the company.
This aggregate rating is based on analysts' research of Vigil Neuroscience and is not a guaranteed prediction by Public.com or investment advice.
Vigil Neuroscience (VIGL) Analyst Forecast & Price Prediction
Start investing in Vigil Neuroscience (VIGL)
Order type
Buy in
Order amount
Est. shares
0 shares